Ustekinumab is safe and effective in pediatric patients with Crohn's disease.

ABSTRACT:

Objectives

Real-world data on ustekinumab for the treatment of pediatric Crohn's disease (CD) are limited. This study sought to evaluate the effectiveness, long-term durability, and safety of ustekinumab in the treatment of children with CD.

Methods

A retrospective longitudinal cohort study of children with CD treated with ustekinumab from two large centers between 2015 and 2020 was performed. The primary outcome was frequency of steroid-free clinical remission at 1 year. Secondary outcomes included time to steroid-free clinical remission, frequency of clinical and biochemical remission, drug escalation and discontinuation, serum level data, and adverse events. Standard descriptive and comparative statistics were performed. Logistic regression was used to identify factors as

SUBMITTER: Mitchel EB 

PROVIDER: S-EPMC12665283 | biostudies-literature | 2025 Apr

REPOSITORIES: biostudies-literature